[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"other-protocol-specified-criteria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:other-protocol-specified-criteria":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100525931",false,"NCT06128148","Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors","JYP0322","Key Inclusion Criteria\n\n* Adult patients age 18 years or older.\n* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ROS1 molecular fusion.\n* Measurable disease according to RECIST version 1.1\n* Life expectancy of at least 3 months\n* Other protocol specified criteria\n\nKey Exclusion Criteria:\n\n* Current participation in another therapeutic clinical trial.\n* Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n* A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug.\n* Known active infections (bacterial, viral including HIV positivity).\n* Other protocol specified criteria","ALL","18 Years",{"count":19,"type":20},101,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced\u002Fmetastatic solid tumors .",[26,27,28,29],"Protein Kinase Inhibitors","Other Protocol Specified Criteria","Lung Neoplasms","Brain Neoplasms",[31,32,33,34],"ROS1 Fusions","ROS1 Gene Rearrangements","Primary brain tumors","ROS1","RECRUITING","2025-07-09",{"date":38,"type":39},"2025-07-14","ACTUAL",{"date":41,"type":39},"2022-05-04",{"date":43,"type":20},"2027-12-30",{"name":45,"class":46},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY",""]